| GeneLibs

题目:: De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer.
作者:: Madrid-Paredes(Adela),Cañadas-Garre(Marisa),Sánchez-Pozo(Antonio),Calleja-Hernández(Miguel Ángel)
状态:: 发布时间2015-09-15 , 更新时间 2015-09-15
期刊:: Pharmacogenomics
摘要:: Therapies targeting HER2 receptor, overexpressed in 20% breast cancer (BC), improved prognosis, however ~62% patients experiment progression during the first year. Molecular mechanisms proposed to be responsible for this de novo resistance include HER2 modifications, defects in the antibody dependent cellular cytotoxicity or in cell arrest and apoptosis or alterations in HER2 signaling components. This article will review the influence of genetic markers investigated to date as cause of de novo resistance to HER2-targeted drugs in HER2-positive BC patients. Biomarkers like p95HER2, CCND1 and CDC25A have demonstrated clinical relevance and prognostic value in HER2-positive BC patients. However, the prognostic value of most biomarkers investigated to date, such as PIK3CA or AKT1, cannot be fully established yet.
语言:: eng
DOI:: 10.2217/pgs.15.88

文献库文献相关信息